TargEDys announces the publication of the first double-blind, randomized, placebo-controlled clinical trial showing Hafnia alvei's efficacy at an unprecedented level in weight loss and satiety

PR89977

LONGJUMEAU, France, June 08, 2021 /PRNewswire=KYODO JBN/ --

    The French biotech TargEDys specialized in breakthrough microbiome-based

solutions announces the publication of its study conducted in 230 overweight

adults supplemented for 12 weeks, confirming the efficacy of the precision

probiotic Hafnia alvei HA4597(R) to improve weight loss, hip circumference

reduction and metabolic parameters thanks to the action of the probiotic and

its postbiotic ClpB on feeling of fullness.

    Mechanistic and preclinical studies showed Hafnia alvei is able to produce

Caseinolytic peptidase B, a protein mimicking the hormone of satiety alpha-MSH,

and to reduce food intake in murine models of obesity. These new results

confirm the efficacy of this PreciBiomic(TM) strain in supporting feeling of

fullness and weight loss in overweight subjects, as well as reducing hip

circumference and glycemia.

    With an average of 3,6% weight loss in 12 weeks in the probiotic group,

Hafnia alvei is dramatically more effective than any other probiotic studied in

weight management, and this level of impact fills the gap between the sectors

of food supplements and drugs. It also drives innovation in the probiotics

field, shifting the approach to precision probiotics, with enhanced efficacy

thanks to the precise understanding of the molecular mechanism of action.

    Hafnia alvei can be found in the products EnteroSatys(R) and Satylia(R) in

France, Portugal, Italy and Slovenia, and TargEDys is looking for distribution

partners to make this breakthrough solution for the prevention of obesity

available to consumers worldwide.

    Grégory Lambert, CEO of TargEDys, declares:

    "This will be a game-changer in the sector of weight management, with

finally a solution that meets consumers expectations in terms of safety and

naturality, while also bringing a real, demonstrated efficacy based on

molecular mimicry and the biochemical regulation of appetite."

    About TargEDys(R)

    TargEDys(R) is a commercial-stage French biotech specialized in the

development of nutraceutical solutions for the control of appetite through

microbiome interventions. The company is the fruit of 15 years of research on

the microbiota conducted within academic laboratories. The company developed

and started the commercialization of its first product based on the PreciBiomic

strain Hafnia alvei HA4597(TM) and develops a product portfolio focusing on

overweight, undernutrition and mental health, all based on the concept of

precibiomic strains backed by a molecular mechanism of action and in vivo

studies.

    More information at www.targedys.com

    Contact: Arnaud Faure & Nina Vinot; bd@targedys.com  

    Logo: https://mma.prnewswire.com/media/1528261/Targedys_Logo.jpg

    Source: TargEDys